Is Tivicay Approved for Children?
Tivicay (dolutegravir), an integrase strand transfer inhibitor for HIV treatment, is FDA-approved for pediatric patients weighing at least 3 kg (about 6.6 lbs). Approval covers ages from birth in some formulations, primarily for treatment-naive or experienced children and adolescents with HIV-1.[1]
What Ages and Weights Qualify?
- Tablets and oral suspension: Approved for children ≥3 kg, including infants from birth in specific cases.
- Dosing starts at 5 mg for the smallest patients, scaling up by weight bands (e.g., 25 mg for 6-10 kg, up to adult doses for ≥50 kg).
- Used in combination with other antiretrovirals; not for monotherapy.[1][2]
How Does It Compare to Adult Use?
Pediatric dosing mirrors adult pharmacokinetics but adjusts for body weight to maintain efficacy and safety. Studies like IMPAACT P1093 and ODYSSEY trial confirmed similar viral suppression rates (around 85-90% at 48 weeks) in children as in adults, with no new resistance signals.[3]
What Side Effects Do Kids Experience?
Common issues match adults: headache, insomnia, nausea. Rare serious risks include hypersensitivity reactions and neural tube defects in pregnancy exposure (not directly pediatric but relevant for adolescent girls). Long-term data show good tolerability, though weight gain is monitored more closely in youth.[1][4]
When Was Pediatric Approval Granted?
Initial pediatric approval came in 2015 for ≥30 kg; expanded in 2018-2021 to lower weights via the oral suspension. EU and WHO also endorse it as first-line for children.[2][5]
Are There Alternatives for Younger Kids?
For infants <3 kg, options include raltegravir (Isentress) or lopinavir/ritonavir. Tivicay's once-daily dosing and high barrier to resistance make it preferred for most eligible children over twice-daily alternatives.[3]
[1]: FDA Tivicay Label
[2]: ViiV Healthcare Prescribing Info
[3]: NEJM ODYSSEY Trial Results
[4]: CDC Pediatric HIV Guidelines
[5]: WHO HIV Treatment Guidelines